Should rosuvastatin be withdrawn from the market?

Lancet. 2004;364(9445):1577; author reply 1578-9. doi: 10.1016/S0140-6736(04)17301-7.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Drug Approval
  • Drug Utilization
  • Fluorobenzenes / adverse effects*
  • Fluorobenzenes / therapeutic use
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects*
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Netherlands
  • Product Surveillance, Postmarketing
  • Pyrimidines / adverse effects*
  • Pyrimidines / therapeutic use
  • Rosuvastatin Calcium
  • Sulfonamides / adverse effects*
  • Sulfonamides / therapeutic use

Substances

  • Fluorobenzenes
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Pyrimidines
  • Sulfonamides
  • Rosuvastatin Calcium